Literature DB >> 34812232

Expression of Vascular Cell Adhesion Molecule-1 in Peripheral Artery Disease is Enriched in Patients with Advanced Kidney Disease.

Po-Tseng Lee1,2, I-Chuang Liao3,2, Cheng-Han Lee1, Ling-Wei Hsu4, Ping-Yen Liu1,2.   

Abstract

BACKGROUND: Serving as an inflammatory biomarker in patients under regular hemodialysis (HD), the arterial tissue expression of vascular cell adhesion molecule 1 (VCAM-1) in patients with different renal function has rarely been investigated and remains unclear.
METHODS: Fifty-one consecutive patients with peripheral arterial disease (PAD) who underwent percutaneous transluminal angioplasty were recruited and divided into a normal renal function group, chronic kidney disease (CKD) group, and HD group. Background disease, clinical and angiographic severity, and serum level of VCAM-1 in the three groups were analyzed. The tissue expression of VCAM-1 was quantitatively demonstrated by immunohistochemical (IHC) staining and protein extraction from cell membranes in another amputated cohort.
RESULTS: In PAD patients, the serum level of VCAM-1 was significantly elevated in the HD group compared with the other two groups (1990.2 ± 607.1 ng/ml vs. 1547.9 ± 511.2 ng/ml vs. 1161.0 ± 435.8 ng/ml, p < 0.001). Serum VCAM-1 was a prognostic factor of major adverse cardiac or limb events (odds ratio: 1.002, 95% confidence interval: 1.001-1.003, p = 0.003). The expression of VCAM-1 was higher in the PAD amputated arterial tissue of CKD and HD patients as demonstrated by quantitative analysis of IHC staining and quantitative membrane protein extraction.
CONCLUSIONS: VCAM-1 is a cardiovascular prognostic biomarker. Both serum level and the tissue expression of VCAM-1 were significantly higher in PAD patients with advanced kidney disease.

Entities:  

Keywords:  Chronic kidney disease; Hemodialysis

Year:  2021        PMID: 34812232      PMCID: PMC8593482          DOI: 10.6515/ACS.202111_37(6).20210701B

Source DB:  PubMed          Journal:  Acta Cardiol Sin        ISSN: 1011-6842            Impact factor:   2.672


  26 in total

1.  Bypass versus Angioplasty in Severe Ischaemia of the Leg (BASIL) trial: An intention-to-treat analysis of amputation-free and overall survival in patients randomized to a bypass surgery-first or a balloon angioplasty-first revascularization strategy.

Authors:  Andrew W Bradbury; Donald J Adam; Jocelyn Bell; John F Forbes; F Gerry R Fowkes; Ian Gillespie; Charles Vaughan Ruckley; Gillian M Raab
Journal:  J Vasc Surg       Date:  2010-05       Impact factor: 4.268

2.  Hemodialysis procedure does not affect the levels of sICAM-1 and sVCAM-1 in patients with end stage renal disease.

Authors:  Vasilios Liakopoulos; Theodoros Eleftheriadis; Theodoros Kyropoulos; Georgios Voliotis; Spyridon Potamianos; Nikolaos Zengos; Ioannis Stefanidis; Bernhard Heintz
Journal:  Ren Fail       Date:  2005       Impact factor: 2.606

3.  Endothelial dysfunction, inflammation and atherosclerosis in chronic kidney disease--a cross-sectional study of predialysis, dialysis and kidney-transplantation patients.

Authors:  Alejandro Recio-Mayoral; Debasish Banerjee; Chris Streather; Juan Carlos Kaski
Journal:  Atherosclerosis       Date:  2011-02-18       Impact factor: 5.162

4.  Cytokine stimulated vascular cell adhesion molecule-1 (VCAM-1) ectodomain release is regulated by TIMP-3.

Authors:  Robert J R Singh; Justin C Mason; Elaine A Lidington; Dylan R Edwards; Robert K Nuttall; Rama Khokha; Vera Knauper; Gillian Murphy; Jelena Gavrilovic
Journal:  Cardiovasc Res       Date:  2005-03-29       Impact factor: 10.787

5.  Major Adverse Limb Events and Mortality in Patients With Peripheral Artery Disease: The COMPASS Trial.

Authors:  Sonia S Anand; Francois Caron; John W Eikelboom; Jackie Bosch; Leanne Dyal; Victor Aboyans; Maria Teresa Abola; Kelley R H Branch; Katalin Keltai; Deepak L Bhatt; Peter Verhamme; Keith A A Fox; Nancy Cook-Bruns; Vivian Lanius; Stuart J Connolly; Salim Yusuf
Journal:  J Am Coll Cardiol       Date:  2018-03-11       Impact factor: 24.094

6.  Plasma levels of IL-1 beta, TNF alpha and their specific inhibitors in undialyzed chronic renal failure, CAPD and hemodialysis patients.

Authors:  B J Pereira; L Shapiro; A J King; M E Falagas; J A Strom; C A Dinarello
Journal:  Kidney Int       Date:  1994-03       Impact factor: 10.612

7.  Chronic kidney disease and the short-term risk of mortality and amputation in patients hospitalized for peripheral artery disease.

Authors:  Philippe Lacroix; Victor Aboyans; Ileana Desormais; Thierry Kowalsky; Jean Pierre Cambou; Joel Constans; Alessandra Bura Rivière
Journal:  J Vasc Surg       Date:  2013-06-14       Impact factor: 4.268

8.  Circulating cell adhesion molecules and endothelial markers before and after transluminal angioplasty in peripheral arterial occlusive disease.

Authors:  D A Tsakiris; M Tschöpl; K Jäger; W E Haefeli; F Wolf; G A Marbet
Journal:  Atherosclerosis       Date:  1999-01       Impact factor: 5.162

9.  Clopidogrel Protects Endothelium by Hindering TNFα-Induced VCAM-1 Expression through CaMKKβ/AMPK/Nrf2 Pathway.

Authors:  Huabing Yang; Pengjun Zhao; Shiliu Tian
Journal:  J Diabetes Res       Date:  2015-12-28       Impact factor: 4.011

10.  Galectin-3 Interacts with Vascular Cell Adhesion Molecule-1 to Increase Cardiovascular Mortality in Hemodialysis Patients.

Authors:  Wen-Chin Ko; Cheuk-Sing Choy; Wei-Ning Lin; Shu-Wei Chang; Jian-Chiun Liou; Tao-Hsin Tung; Chih-Yu Hsieh; Jia-Feng Chang
Journal:  J Clin Med       Date:  2018-09-24       Impact factor: 4.241

View more
  2 in total

1.  Stage II of Chronic Kidney Disease-A Tipping Point in Disease Progression?

Authors:  Lovorka Grgurevic; Rudjer Novak; Grgur Salai; Stela Hrkac; Marko Mocibob; Ivana Kovacevic Vojtusek; Mario Laganovic
Journal:  Biomedicines       Date:  2022-06-27

2.  Serum VCAM-1 and ICAM-1 measurement assists for MACE risk estimation in ST-segment elevation myocardial infarction patients.

Authors:  Jiancai Yu; Yongxing Liu; Wanzhong Peng; Zesheng Xu
Journal:  J Clin Lab Anal       Date:  2022-08-31       Impact factor: 3.124

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.